- Home
- EXEL vs ACI Comparison
EXEL vs ACI Comparison
Compare EXEL & ACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | ACI |
|---|---|---|
| Founded | 1994 | 1860 |
| Country | United States | United States |
| Employees | N/A | 270000 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Food Chains |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 9.3B |
| IPO Year | 2000 | 2015 |
Fundamental Metrics
Financial Performance| Metric | EXEL | ACI |
|---|---|---|
| Price | $44.47 | $16.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 15 |
| Target Price | ★ $46.50 | $22.00 |
| AVG Volume (30 Days) | 2.1M | ★ 6.9M |
| Earning Date | 05-05-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 4.13% |
| EPS Growth | ★ 57.95 | N/A |
| EPS | ★ 2.78 | 0.40 |
| Revenue | $452,477,000.00 | ★ $83,172,500,000.00 |
| Revenue This Year | $13.61 | $0.68 |
| Revenue Next Year | $13.13 | $1.47 |
| P/E Ratio | ★ $16.05 | $42.19 |
| Revenue Growth | N/A | ★ 3.46 |
| 52 Week Low | $33.76 | $15.80 |
| 52 Week High | $48.74 | $22.78 |
Technical Indicators
Market Signals| Indicator | EXEL | ACI |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 48.51 |
| Support Level | $40.98 | $16.49 |
| Resistance Level | $46.66 | $17.66 |
| Average True Range (ATR) | 1.37 | 0.49 |
| MACD | -0.13 | -0.01 |
| Stochastic Oscillator | 23.86 | 72.58 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About ACI Albertsons Companies Inc.
Albertsons is the second-largest supermarket operator in the United States with about 2,300 stores across a variety of banners. Around 80% of the firm's sales comes from nonperishable and fresh food, of which 26% comes from its portfolio of private brands. The company operates fuel centers at about 20% of its store locations and pharmacies at 75%. Albertsons went public in 2020 following years of ownership under private equity firm Cerberus Capital Management, which still owns about a fourth of the outstanding shares.